KR100638053B1 - Cosmetic composition for abirritating skin containing extract of rumex crispus as active ingredient - Google Patents
Cosmetic composition for abirritating skin containing extract of rumex crispus as active ingredient Download PDFInfo
- Publication number
- KR100638053B1 KR100638053B1 KR1020050034452A KR20050034452A KR100638053B1 KR 100638053 B1 KR100638053 B1 KR 100638053B1 KR 1020050034452 A KR1020050034452 A KR 1020050034452A KR 20050034452 A KR20050034452 A KR 20050034452A KR 100638053 B1 KR100638053 B1 KR 100638053B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- skin irritation
- cosmetic composition
- skin
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 239000002537 cosmetic Substances 0.000 title claims abstract description 48
- 235000021501 Rumex crispus Nutrition 0.000 title claims abstract description 7
- 240000004284 Rumex crispus Species 0.000 title claims abstract 4
- 239000004480 active ingredient Substances 0.000 title claims description 10
- 231100000475 skin irritation Toxicity 0.000 claims abstract description 48
- 230000036556 skin irritation Effects 0.000 claims abstract description 48
- 206010040880 Skin irritation Diseases 0.000 claims abstract description 46
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000004310 lactic acid Substances 0.000 claims abstract description 20
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 229940058015 1,3-butylene glycol Drugs 0.000 claims abstract description 10
- 235000019437 butane-1,3-diol Nutrition 0.000 claims abstract description 10
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims abstract description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 6
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims abstract description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims abstract description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract description 3
- 229960004275 glycolic acid Drugs 0.000 claims abstract description 3
- 229960000448 lactic acid Drugs 0.000 claims abstract description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229930002330 retinoic acid Natural products 0.000 claims abstract description 3
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 3
- 229960001727 tretinoin Drugs 0.000 claims abstract description 3
- 239000006071 cream Substances 0.000 claims description 20
- 238000009472 formulation Methods 0.000 claims description 19
- 235000019441 ethanol Nutrition 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 206010015150 Erythema Diseases 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 231100000321 erythema Toxicity 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- -1 pack Substances 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 238000004040 coloring Methods 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000004927 skin cell Anatomy 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 description 5
- 235000014459 Sorbus Nutrition 0.000 description 5
- 241001092391 Sorbus Species 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 229940010747 sodium hyaluronate Drugs 0.000 description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 229960000458 allantoin Drugs 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 231100000021 irritant Toxicity 0.000 description 4
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 4
- 230000037307 sensitive skin Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 3
- 244000207667 Rumex vesicarius Species 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002269 analeptic agent Substances 0.000 description 3
- 229940079894 benzophenone-9 Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229960001238 methylnicotinate Drugs 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 229950011392 sorbitan stearate Drugs 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000003578 releasing effect Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049294 glyceryl stearate se Drugs 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002718 inhibitory effect on inflammation Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000035909 sensory irritation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
- B60R1/00—Optical viewing arrangements; Real-time viewing arrangements for drivers or passengers using optical image capturing systems, e.g. cameras or video systems specially adapted for use in or on vehicles
- B60R1/02—Rear-view mirror arrangements
- B60R1/06—Rear-view mirror arrangements mounted on vehicle exterior
- B60R1/0602—Rear-view mirror arrangements mounted on vehicle exterior comprising means for cleaning or deicing
-
- B08B1/143—
-
- B08B1/20—
-
- B08B1/32—
Abstract
Description
본 발명은 피부자극 완화용 화장료 조성물에 관한 것으로, 보다 상세하게는, 소루쟁이 추출물을 유효성분으로 함유하는 피부자극 완화용 화장료 조성물을 제공한다.The present invention relates to a cosmetic composition for alleviating skin irritation, and more particularly, to provide a cosmetic composition for alleviating skin irritation, which contains an extract of Sorugyun as an active ingredient.
최근 민감 피부라고 느끼는 소비자가 증가하는 추세에 있다. 일반 소비자를 대상으로 한 의식조사에서 자신이 민감 피부라고 회답한 비율이 30-40% 정도였으며, 이러한 비율은 계속 증가하는 추세이다. 이처럼 민감 피부라고 느끼는 비율이 증가하고 있는 요인은 오존층 파괴에 따른 자외선 조사량 증가, 생활공간의 건조화, 개인의 알레르기 체질, 스트레스, 화학유해 물질의 증가 등이다. 한편으로 최근 소비자의 지향이 자연 친화적, 저자극으로 이행되고 있는 것도 민감 피부에 대한 의식을 향상시키는 요인이 되고 있는 것으로 추측되고 있으며, 이에 따라 화장 품에 의한 피부자극을 완화시켜 주는 물질에 대한 관심이 높아지고 있다.Recently, the number of consumers who feel sensitive skin is increasing. In the survey of general consumers, 30-40% of respondents said they were sensitive skin, and this rate is increasing. The increasing rate of sensitive skin is due to the increase in ultraviolet radiation due to the destruction of the ozone layer, the drying of the living space, the constitution of allergies, stress, and the increase of chemical harmful substances. On the other hand, the recent shift toward consumer-friendly and hypoallergenic consumerism has also been suggested to be a factor in improving awareness of sensitive skin. Accordingly, interest in substances that alleviate skin irritation caused by cosmetic products Is rising.
일반적으로 화장품을 만들기 위해서는 다양한 원료들이 사용되며 통상적으로는 20종 내지 50여종의 원료를 사용하게 된다. 이들 원료들은 피부자극 검사를 통하여 그 안전성이 입증되었으나, 제품에 적용되는 경우 피부에 염증, 가려움증 및 알레르기 등의 자극을 일으킬 수 있다. 그러나, 이러한 자극 반응들이 모든 사람에게 일어나는 것은 아니며, 특정인에게만 일어날 수도 있다.In general, various raw materials are used to make cosmetics, and typically 20 to 50 kinds of raw materials are used. These ingredients have been proved to be safe through skin irritation tests, but when applied to the product can cause irritation, itching and allergies to the skin. However, these stimulus reactions do not happen to everyone, and may only happen to certain people.
화장품의 사용에 의해 일어날 수 있는 피부자극에는 가려움 (itching), 따끔거림 (stinging) 및 화끈거림 (burning) 등의 자극감과 홍반 (erythema) 및 부종 (edema) 등이 있다. 접촉성 피부염으로는 자극성 접촉 피부염, 알레르기성 접촉 피부염, 감각성 자극 및 광독성 피부염 등이 있으나, 이들을 명확하게 구별하기는 어려우며 서로 혼합되어 일어나는 경우가 대부분이다.Skin irritation that may occur with the use of cosmetics includes irritation such as itching, stinging and burning, and erythema and edema. Contact dermatitis includes irritant contact dermatitis, allergic contact dermatitis, sensory irritation, and phototoxic dermatitis, but it is difficult to clearly distinguish them, and most of them are mixed with each other.
무엇보다도 피부자극이 일어나기 위해서는 우선 화장품에 의한 피부 침투가 일어나야 하며, 이들이 표피 혹은 진피 세포와 상호 작용을 함으로써 면역체계가 활성화되어 자극이 일어난다고 할 수 있다. 이러한 피부자극을 완화하기 위해서 피부자극 유발 물질을 제거하는 방법 등 다양한 방법이 동원되었으나, 최근에는 기능성 화장품 제조가 늘어나고 있다.Above all, in order for skin irritation to occur, first, skin penetration by cosmetics must occur, and they interact with the epidermis or dermis cells to activate the immune system and cause irritation. In order to alleviate such skin irritation, various methods, such as a method of removing skin irritation-inducing substances, have been mobilized, but functional cosmetics have recently been increasing.
이에, 화장품 제조업자들은 일반적으로 사용되는 자극 완화 물질을 제품에 적용시켜줌으로써 화장품 원료의 자극을 최소화시키기 위한 노력을 진행하고 있다. 그러나, 기능성 원료 자체가 자극원으로 작용하는 경우가 허다하기 때문에 이와 같 은 연구는 한계가 있다고 할 수 있다. 따라서, 기능성 원료의 효과를 그대로 유지하면서 화장품에 의한 부작용을 줄이고 피부자극을 완화할 수 있는 물질의 선별이 필요하다.Therefore, cosmetics manufacturers are making efforts to minimize the irritation of the cosmetic raw material by applying a commonly used irritant substance to the product. However, this study is limited because the functional material itself often acts as an irritant. Therefore, it is necessary to select a substance that can reduce side effects caused by cosmetics and alleviate skin irritation while maintaining the effects of the functional raw materials.
본 발명자들은 상술한 당업계의 요구를 해결하고자 예의 노력한 결과, 소루쟁이 추출물이 자극물질로부터 세포자극을 완화하고 염증을 억제하는 효과가 우수함을 확인하였고, 이를 화장료에 사용할 경우 피부자극을 완화하는 효과가 뛰어남을 확인하여 본 발명을 완성하였다.The present inventors have diligently tried to solve the above-described needs of the art, and as a result, it was confirmed that the extract of Soru-Jiung has an excellent effect of alleviating cellular stimulation and suppressing inflammation from the irritant, and when used in cosmetics, the effect of alleviating skin irritation It was confirmed that the excellent to complete the present invention.
따라서, 본 발명의 목적은 소루쟁이 추출물을 유효 성분으로 포함하는 피부자극 완화용 화장료 조성물을 제공하는 데 있다.Accordingly, it is an object of the present invention to provide a cosmetic composition for skin irritation relief comprising the extract of Soru-Jin as an active ingredient.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명 및 청구범위에 의해 보다 명확하게 된다.Other objects and advantages of the present invention will become apparent from the following detailed description and claims.
본 발명의 양태에 따르면, 본 발명은 소루쟁이 (Rumex crispus) 추출물을 유효성분으로 함유하는 피부자극 완화용 화장료 조성물을 제공한다.According to an aspect of the present invention, the present invention provides a cosmetic composition for alleviating skin irritation containing Rumex crispus extract as an active ingredient.
본 발명자들은 다수의 천연물을 원료로 하여 추출물을 제조하였고, 자극원으 로부터의 세포자극 완화 및 염증 억제 효과가 우수한 물질을 선별하는 작업을 수행한 결과, 소루쟁이 추출물이 상술한 본 발명의 목적에 가장 부합된다는 사실을 발견하게 되었다.The inventors of the present invention have prepared extracts using a large number of natural products as a raw material, and as a result of performing the work of selecting substances excellent in stimulating cell stimulation and inhibiting inflammation from stimulants, the extracts of Soru-Jiung are most suitable for the purpose of the present invention described above. I found that it was a match.
소루쟁이 (Rumex crispus)는 양제근, 솔쟁이 또는 송구지 등으로 불리며, 한여름이면 줄기가 다 말라 버렸다가 선선하면 다시 자라나는 마디풀과의 여러해살이풀이다. 어린잎은 나물로 먹기도 하며, 백선, 무좀 및 습진 등에 효과가 있다고 한다. 예로부터 민간에서는 개선, 옴 및 피부암 등의 피부병에 사용하였으며, 방광염, 대장염 등에도 달여서 사용했다고 한다. 가을에 뿌리를 캐서 둥글게 말아 햇볕에 말린 것을 양제근이라고 하며, 이를 대황이라는 한약품에 대용하기도 하였다. Rumex crispus is called perennial herb, canopy, or muzzle, and is a perennial herb that grows dry in midsummer and grows again when cool. Young leaves are eaten as herbs and are effective for ringworm, athlete's foot and eczema. Since ancient times, it has been used for skin diseases such as amelioration, scabies and skin cancer, and it has been used for cystitis and colitis. In the fall, the roots were dug up and rolled up and dried in the sun called Yangje-geun, which was substituted for the Chinese medicine called rhubarb.
본 발명의 화장료 조성물의 유효성분인 소루쟁이 추출물은 신규 효능인 자극원으로부터의 세포자극 완화 및 항염증 효과가 있다.Soru-Ji extract, an active ingredient of the cosmetic composition of the present invention, has an anti-inflammatory and anti-inflammatory effect from a novel stimulating source.
본 발명에 있어서, 소루쟁이 추출물은 소루쟁이의 다양한 기관 또는 부분 (예: 잎, 꽃, 뿌리, 줄기, 가지, 껍질 및 과실 등)으로부터 추출하여 얻은 것을 의미하고, 바람직하게는 소루쟁이의 모든 기관인 소루쟁이 풀 전체로부터 얻은 추출물을 의미한다.In the present invention, the extract is derived from various organs or parts (eg, leaves, flowers, roots, stems, branches, shells, fruits, etc.) of the sarcasm, preferably all organs of the sarcasm. Means an extract obtained from the whole of the grass.
본 발명의 소루쟁이 추출물은 당업계에 공지된 통상의 방법에 따라, 즉, 통상적인 온도와 압력의 조건하에서, 통상적인 용매를 사용하여 제조될 수 있다.The extracts of the present invention can be prepared according to conventional methods known in the art, i.e., under conventional conditions of temperature and pressure, using conventional solvents.
본 발명의 조성물의 유효성분인 소루쟁이 추출물은 물, 탄소수 1-4개의 무수 또는 함수 저급 알코올, 아세톤, 에틸아세테이트, 부틸아세테이트 및 1,3-부틸렌 글리콜로 구성된 군으로부터 선택되는 용매를 사용하여 추출되는 것이 바람직하며, 보다 바람직하게는 에틸 알코올이며, 보다 더 바람직하게는 50-90% 에틸 알코올이고, 가장 바람직하게는 70% 에틸 알코올이다. 상기 추출 용매의 적합한 양은 소루쟁이 건조 중량의 1-10 배이며, 보다 바람직하게는 1-5배이다.Soruja extract, which is an active ingredient of the composition of the present invention, is prepared using a solvent selected from the group consisting of water, anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, butyl acetate, and 1,3-butylene glycol. Preference is given to extracting, more preferably ethyl alcohol, even more preferably 50-90% ethyl alcohol, most preferably 70% ethyl alcohol. A suitable amount of the extraction solvent is 1-10 times the dry weight of the boric acid, more preferably 1-5 times.
본 발명의 소루쟁이 추출물은 다음의 단계를 포함하는 과정에 의해 제조된다: (a) 소루쟁이에 1-5배의 물, 탄소수 1-4개의 무수 또는 함수 저급 알코올, 아세톤, 에틸아세테이트, 부틸아세테이트 및 1,3-부틸렌 글리콜로 구성된 군으로부터 선택되는 용매를 첨가하여 침전시키는 단계; (b) 단계 (a)의 용매 첨가된 소루쟁이를 여과한 뒤 40-100℃에서 농축하는 단계; 및 (c) 상기 단계 (b)에서 농축한 성분을 여과 및 건조하여 1,3-부틸렌 글리콜에 용해하는 단계.An extract of the present invention is prepared by a process comprising the following steps: (a) 1 to 5 times water, 1-4 anhydrous or hydrous lower alcohols, acetone, ethyl acetate, butyl acetate And adding a solvent selected from the group consisting of 1,3-butylene glycol; (b) filtering the solvent added boricum of step (a) and concentrating at 40-100 ° C .; And (c) filtering and drying the components concentrated in step (b) to dissolve in 1,3-butylene glycol.
본 발명의 구체적인 일 실시예에 따르면, 상술한 추출 과정은 다음과 같이 실시된다: 우선, 원료가 되는 소루쟁이를 세척, 건조 및 작은 조각으로 파쇄한 다음 70% 에틸 알코올을 소루쟁이 건조중량의 5배 부피비로 첨가하여 5일 동안 침전시킨다. 이어, 300 메쉬에 여과한 다음, 진공 감압 농축기를 이용하여 80℃에서 농축하여 소루쟁이 추출물 파우더를 얻은 다음 제품에 적용하기 위해 1,3-부틸렌 글리콜에 용해시킴으로써 소루쟁이 추출물을 제조한다.According to one specific embodiment of the present invention, the above-described extraction process is carried out as follows: first, the raw sorbet is washed, dried and broken into small pieces, and then 70% ethyl alcohol is dried at 5% of dry weight. Precipitate for 5 days by addition in fold volume ratio. The sorbus extract is then prepared by filtration at 300 mesh and then concentrating at 80 ° C. using a vacuum decompression concentrator to obtain sorbus extract powder and then dissolving it in 1,3-butylene glycol for application to the product.
한편, 본 발명의 소루쟁이 추출물은 상술한 추출법에 의한 추출물뿐만 아니라, 통상적인 정제 과정을 거친 추출물도 포함한다. 예컨대, 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 이용한 분리, 다양한 크로마토그래피 (크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실 시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 소루쟁이 추출물에 포함된다고 해석된다.On the other hand, the rubbing extract of the present invention includes not only the extract by the above-described extraction method, but also the extract that has undergone a conventional purification process. Obtained by various additional purification methods, such as, for example, separation using ultrafiltration membranes having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity). Fractions are also construed as being included in the extract of the present invention.
본 발명의 소루쟁이 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.Soruja extract of the present invention may be prepared in a powder state by an additional process such as vacuum distillation and freeze drying or spray drying.
본 발명의 바람직한 구현예에 따르면, 소루쟁이 추출물의 함량은 본 발명의 피부자극 완화용 화장료 조성물 총 중량에 대하여 0.0001-10.0 중량%이다. 소루쟁이 추출물의 함량이 0.0001% 미만일 때에는 그 효과가 나타나기 어렵고, 10% 이상일 때에는 오히려 피부에 자극을 유발할 가능성이 높으며, 제형의 안정화에도 큰 영향을 미칠 수 있다. 보다 바람직하게는, 본 발명의 피부자극 완화용 화장료 조성물에 포함되는 소루쟁이 추출물의 함량은 0.5-5%이며, 가장 바람직하게는 1.0-3.0%이다.According to a preferred embodiment of the present invention, the content of Soru-Ji extract is 0.0001-10.0% by weight relative to the total weight of the skin composition for alleviating the skin irritation of the present invention. When the content of the extract is less than 0.0001%, the effect is less likely to appear, and when more than 10% is more likely to cause irritation on the skin, it may also have a significant effect on the stabilization of the formulation. More preferably, the content of the sorujeuk extract contained in the cosmetic composition for alleviating the skin irritation of the present invention is 0.5-5%, most preferably 1.0-3.0%.
본 발명의 화장료 조성물은 소루쟁이 추출물을 유효 성분으로 포함하는 조성물로서 제조되어, 피부자극성이 큰 화장료 조성물을 피부에 적용하기 전 또는 적용한 후에 적용될 수 있다. 또한, 소루쟁이 추출물을 피부자극성이 큰 화장료 조성물에 추가적으로 첨가시켜 피부에 적용될 수도 있다.The cosmetic composition of the present invention may be prepared as a composition comprising the extract of Soru-Jin as an active ingredient, and may be applied before or after applying the cosmetic composition having high skin irritation to the skin. In addition, the extract may be applied to the skin by additionally added to the cosmetic composition having a large skin irritation.
피부자극성이 큰 화장료 조성물은 락트산 (lactic acid), 글리콜산 (glycolic acid), 살리실산 (salicylic acid) 및 레티노산 (retinoic acid)으로 구성된 군으로부터 선택되며, 바람직하게는 락트산이다. 따라서, 본 발명의 다른 양태에 따르면, 본 발명은 피부자극 완화제로서의 소루쟁이 추출물과 함께 피부자극제인 락트산을 추가로 포함하는 화장료 조성물을 제공한다.The cosmetic composition with high skin irritation is selected from the group consisting of lactic acid, glycolic acid, salicylic acid and retinoic acid, preferably lactic acid. Therefore, according to another aspect of the present invention, the present invention provides a cosmetic composition further comprising lactic acid, a skin stimulant, together with the extract of Soru-Jung as a skin stimulant.
본 발명의 화장료 조성물에 포함되는 성분은 유효 성분으로서 상기 소루쟁이 추출물 이외에 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.The ingredients included in the cosmetic composition of the present invention include ingredients commonly used in the composition in addition to the extracts as the active ingredient, and include, for example, conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings, And carriers.
본 발명의 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 본 발명의 조성물이 화장료 조성물로 사용될 때에는 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The compositions of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, It may be formulated as an oil, powder foundation, emulsion foundation, wax foundation, spray, and the like, but is not limited thereto. More specifically, when the composition of the present invention is used as a cosmetic composition, it is prepared in the form of a flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder Can be.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular in the case of a spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해 화제 또는 유탁화제가 이용되고, 예컨대 물, 에틸 알코올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as the carrier component, such as water, ethyl alcohol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, Fatty acid esters of 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에틸 알코올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, water, diluents such as water, ethyl alcohol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Crystalline cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
본 발명의 소루쟁이 추출물을 함유하는 화장료 조성물은 그 자체만으로도 피부자극을 유발하지 않으며, 화장료 원료 특히 락트산에 의한 피부자극을 크게 감소시키고, 피부자극에 의해 발전되는 염증을 억제시키므로 피부자극에 의해 발전되는 염증을 예방 및 치료하는 효능을 갖는다.The cosmetic composition containing the extract of Soru-Jin of the present invention does not cause skin irritation by itself, greatly reduces skin irritation caused by cosmetic raw materials, especially lactic acid, and suppresses inflammation developed by skin irritation, thereby developing by skin irritation. It has the effect of preventing and treating inflammation.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in more detail, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .
제조예 1 : 소루쟁이 추출물의 제조Preparation Example 1 Preparation of Soru-Zip Extract
세척, 건조한 뒤 곱게 자른 소루쟁이 (Rumex crispus) 1 kg을 에틸 알코올과 물이 7:3(v/v)으로 혼합된 수용액 5 ℓ에 5일 동안 침전시키고, 300 메쉬에 여과한 다음, 진공 감압 농축기를 이용하여 80℃에서 농축시켰다. 이렇게 하여 얻어진 소루쟁이 농축 파우더를 다시 제품에 적용하기 용이하게 1,3-부틸렌 글리콜에 용해시켰다.1 kg of washed, dried and finely cut Rumex crispus was precipitated in 5 L of an aqueous solution of ethyl alcohol and water at 7: 3 (v / v) for 5 days, filtered through 300 mesh, and then vacuum reduced. Concentrated at 80 ° C. using a concentrator. The soruja concentrated powder thus obtained was dissolved in 1,3-butylene glycol for easy application to the product again.
실험예 1 : 락트산에 의한 피부세포 자극에 대한 소루쟁이 추출물의 자극 완화Experimental Example 1: Stimulation of Sorbus extracts against skin cell stimulation by lactic acid
본 발명의 소루쟁이 추출물이 피부자극 완화 효과를 가지는지 확인하기 위해 락트산 (lactic acid)에 의한 세포자극 완화 실험을 수행하였다. 인간 피부 세포인 섬유아세포 (fibroblast)를 DMEM (sigma)이 들어 있는 T-75 플라스크 (Falcon, USA)에서 80%정도 성장할 때까지 배양하고 다시 DMEM이 들어 있는 96-웰 플레이트 (Falcon, USA)에서 1×105 세포/웰이 될 때까지 12시간 동안 배양하였다. 세포 배 양 후, 현미경을 통해 세포가 완전히 부착되어 잘 형성하는지 여부를 확인하고, 피부 세포 자극원으로 0.2% 락트산을 이용하여 다음과 같이 실험을 진행하였다. 상기 락트산의 농도에서 정상 피부 세포는 일반적으로 모두 사멸한다. 섬유아세포가 배양된 상기 플레이트의 96웰 각각에 0.2% 락트산이 함유된 DMEM을 200 ㎕씩 첨가하고, 이어 제조예 1에서 준비된 소루쟁이 추출물을 각각 50, 100, 200, 500 및 1,000 ㎍/㎖로 첨가하였다. 대조군으로는 락트산과 소루쟁이 추출물을 모두 첨가하지 않았고, 비교군으로는 락트산만 첨가한 것과 소루쟁이 추출물만을 첨가한 것을 별도로 준비하였다. In order to confirm that the extract of the present invention, Soru-Ji, has a skin irritation-releasing effect, a cell stimulation relaxation experiment was performed by lactic acid. Human skin cells, fibroblasts, were cultured in T-75 flasks containing DMEM (sigma) (Falcon, USA) until about 80% growth, and then in 96-well plates (Falcon, USA) containing DMEM. Incubate for 12 hours until 1 × 10 5 cells / well. After culturing the cells, the microscope confirmed whether the cells are completely attached and well formed, and experimented as follows using 0.2% lactic acid as a skin cell stimulator. Normal skin cells generally die at the concentration of lactic acid. 200 μl of DMEM containing 0.2% lactic acid was added to each 96 wells of the plate on which the fibroblasts were cultured, and then 50, 100, 200, 500 and 1,000 μg / ml of the extracts prepared in Preparation Example 1, respectively. Added. As a control group, neither lactic acid nor sorbus extract was added, and in the comparative group, only lactic acid and only sorbus extract were added separately.
시험 물질을 첨가하고 12시간이 경과한 후에, 세포의 생존율을 비교하기 위해 MTT ([3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 시약을 각 웰에 10 ㎍씩 첨가하고, 4시간 동안 방치한 후, ELISA 리더 (Molecular Dervices사)를 이용하여 각 웰의 흡광도를 측정하고, 다음과 같은 수학식으로 세포 생존율을 측정하였으며, 그 결과는 다음 표 1과 같다. After 12 h of addition of the test substance, 10 μg of MTT ([3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) reagent was added to each well to compare the viability of the cells. After the addition, and left for 4 hours, the absorbance of each well was measured using an ELISA reader (Molecular Dervices), and cell viability was measured by the following equation, and the results are shown in Table 1 below.
상기 표 1에서 보는 바와 같이, 소루쟁이 추출물은 세포자극이 거의 없어 세포의 생존에 영향을 주지 않았다. 또한, 락트산에 의해 세포가 모두 사멸하는 것이 소루쟁이 추출물의 처리 농도가 증가함에 따라 세포의 생존율이 증가하였다. 따라서, 소루쟁이 추출물은 락트산에 의한 피부세포 자극을 완화시켜 피부세포 사멸을 억제하는 효과가 있음을 알 수 있다.As shown in Table 1, the extract of Soru-Ji had almost no cell stimulation and did not affect cell survival. In addition, the cell death by lactic acid increased the survival rate of the cells as the treatment concentration of the extract was increased. Therefore, it can be seen that the extract of Soru-Jin has an effect of inhibiting skin cell death by alleviating skin cell stimulation caused by lactic acid.
실험예 2 : 항염증 효과 평가법-메틸 니코티네이트를 이용한 평가Experimental Example 2: Evaluation using anti-inflammatory effect evaluation method-methyl nicotinate
피부가 건강한 피험자 20명을 선정하여 상박에 실험을 위한 위치를 결정하고 각 위치에 대하여 크로마미터 (Minolta CR 300, Minolta 사)를 이용하여 피부색을 측정하였다. 피부색을 나타내는 L*, a*, b* 값 중에서 피부의 붉기를 나타내는 a* 값으로 피부색을 평가하였다. 하기 제형예 4의 조성을 갖는 크림에 제조예 1에서 준비한 소루쟁이 추출물을 0.1, 0.2, 0.5 및 1%의 농도로 포함하도록 제조한 크림을 피부 상박에 1시간 간격으로 6회 도포하였다. 마지막으로 제품을 도포한 후 1시간 경과 후에 도포된 샘플을 미온수로 깨끗하게 닦아낸 후 건조시켰다. 건조 30분 경과 후에 염증 유발물질인 0.04% 메틸 니코티네이트 (methyl nicotinate, Aldrich Chemical Company)를 페이퍼 디스크에 80 ㎍를 덜어 흠뻑 적신 후 1분 30초 동안 상박에 올려놓았다. 1분 30초 경과 후 페이퍼 디스크를 제거하고 남아 있는 메틸 니코티네이트를 흐르는 물에 깨끗하게 닦아내었다. 20-30분 후 염증이 유발되면 홍반이 생기는데 이 홍반의 발생 정도를 크로마미터 (Minolta CR 300, Minolta 사)를 이용하여 a*값을 측정하였다. 측정한 a*값을 하기 수학식에 대입하여 염증 억제 효과를 산출한 후 표 2에 그 결과를 나타내었다. 소루쟁이 추출물을 함유하는 크림을 도포하지 않은 실험군을 대조군으로 하였다. 대조군의 염증 억제 효과를 0%로 하여 본 발명의 소루쟁이 추출물의 염증 억제 효과를 비교하였다.Twenty subjects with healthy skin were selected to determine the location for the experiment on the upper arm, and the skin color was measured using a chromameter (Minolta CR 300, Minolta) for each location. Skin color was evaluated by the a * value which shows the redness of skin among L *, a *, and b * values which show skin color. To the cream having the composition of Formulation Example 4, the cream prepared so as to contain the extracts prepared in Preparation Example 1 in concentrations of 0.1, 0.2, 0.5, and 1% was applied to the skin upper arm six times at 1 hour intervals. Finally, after 1 hour after the product was applied, the applied sample was wiped clean with lukewarm water and dried. After 30 minutes of drying, 0.04% methyl nicotinate (Aldrich Chemical Company), an inflammation-inducing agent, was soaked with 80 μg of paper disc and placed on the upper arm for 1 minute and 30 seconds. After 1 minute and 30 seconds, the paper disc was removed and the remaining methyl nicotinate was wiped clean with running water. When inflammation is induced after 20-30 minutes, erythema develops. The a * value of the erythema was measured using a chromameter (Minolta CR 300, Minolta). Substituting the measured a * value into the following equation calculates the inhibitory effect of the inflammation, and the results are shown in Table 2. The experimental group that was not coated with the cream containing the extract was used as a control. Inflammatory inhibitory effect of the control group was set to 0%, and the inflammatory inhibitory effect of the extract of the present invention was compared.
상기 표 2에서 보는 바와 같이, 소루쟁이 추출물을 포함하는 크림은 소루쟁이 추출물의 농도 의존적으로 피부자극에 의해 발전될 수 있는 염증에 대한 억제 효과가 상승하였다. 따라서, 본 발명의 소루쟁이 추출물을 포함하는 화장료 조성물은 염증 억제 효과를 가짐을 알 수 있다.As shown in Table 2, the cream containing the extract of Soru-Jin increased the inhibitory effect on inflammation that may be developed by skin irritation in a concentration-dependent manner of the extract. Therefore, it can be seen that the cosmetic composition comprising the extract of the rubbing extract of the present invention has an anti-inflammatory effect.
실험예 3: 소루쟁이 추출물의 피부자극 완화 효과 I- 인체 피부 첩포 시험Experimental Example 3: Skin irritation relaxing effect of Soru-Ji extract I- Human skin patch test
본 발명의 소루쟁이 추출물을 인체 피부에 직접 적용하였을 때, 피부자극 완화 효과를 가지는지 확인하기 위해 인체 피부 첩포 시험을 하였다. 과거력상 피부자극에 과민반응을 보인 적이 없으며, 현재 피부병 내지 피부 알러지 증상이 없는 피검자 15명을 대상으로 하였다. 피검자의 연령 분포는 25-34세이며, 평균 연령은 29세였다. 하기 표 3의 조성으로 실시예 1, 비교예 1 및 비교예 2의 시험물질을 제조하였다.When the extract of the present invention was directly applied to the human skin, human skin patch test was carried out to check whether it has a skin irritation-releasing effect. The subjects of this study were 15 subjects who had no history of hypersensitivity to skin irritation and have no skin disease or skin allergy. The age distribution of the subjects was 25-34 years old and the mean age was 29 years old. To the test material of Example 1, Comparative Example 1 and Comparative Example 2 was prepared in the composition of Table 3.
우선 시험 부위를 70% 에틸 알코올로 닦아낸 뒤 건조시켰다. 준비된 시험물질을 15 ㎍씩 핀 챔버 (Finn chamber, 100 ×10, EPITEST, 핀란드국) 내에 적하시킨 후 시험 대상자의 전박 (forearm) 안쪽 부위에 밀폐 첩포하였다. 24시간 동안 첩포하고, 첩포를 제거한 후 표시펜으로 시험부위를 표시하였다. 첩포한 후 각각 24시간 후와 48시간 후의 자극 정도를 확대경 (8MC-150, DAZOR, 미합중국)을 이용하여 시험 부위의 홍반 및 부종 유무를 관찰하였다.The test site was first wiped off with 70% ethyl alcohol and dried. 15 μg of the prepared test substance was added dropwise into a Fin chamber (Finn chamber, 100 × 10, EPITEST, Finland), and then sealed in the forearm inner part of the test subject. The patch was applied for 24 hours, the patch was removed, and the test site was marked with a marker pen. After patching, the extent of stimulation after 24 hours and 48 hours, respectively, was examined by using a magnifying glass (8MC-150, DAZOR, United States of America) for erythema and edema.
피부반응은 국제접촉피부염연구회 (ICDRG: International Contact Dermatitis Research Group)의 규정 (표 4)에 따라 판정하였으며, 하기 수학식 3에 의하여 평균 피부 반응도를 계산하고 그 결과를 표 5에 나타내었다.Skin response was determined according to the rules of the International Contact Dermatitis Research Group (ICDRG) (Table 4), the average skin reactivity was calculated by the following equation 3 and the results are shown in Table 5.
상기 표 5를 통해, 소루쟁이 추출물을 포함하는 본 발명의 화장료 조성물은 화장품에서 자극원으로 작용하는 락트산에 의한 피부자극을 크게 감소시킨다는 것을 패치 테스트를 통해 확인하였다.Through Table 5, it was confirmed through the patch test that the cosmetic composition of the present invention comprising the extract of Soru-Ju significantly reduces skin irritation caused by lactic acid acting as a stimulating agent in cosmetics.
실험예 4: 소루쟁이 추출물의 피부자극 완화 효과 II-스팅 (stinging) 테스트Experimental Example 4: Skin irritation relaxing effect II-stinging test
피검자 15명을 대상으로 시험하였으며, 연령분포는 25-33세이며, 평균연령은 30세였다. 스팀 제너레이터 (Steam generator)를 사용하여 15분간 충분히 스위팅 (Sweating)시키고 나서 충분량의 시료 실시예 1 및 비교예 1 (표 3의 조성)을 각각 손에 묻혀 왼쪽과 오른쪽의 코 주위 및 뺨을 중심으로 강하게 비볐다. 스팅 그레이드 (Stinging grade)는 시료 적용 후 자극 반응이 나타나는 시간에 따라 30초 이내에 나타나는 경우를 Intensive stinging, 2.5분을 Mild stinging, 5분을 Moderate stinging, 그리고 8분 이내에 나타나는 경우를 Delayed stinging으로 분류하여 평가한 뒤 그 결과를 표 6에 나타내었다.The subjects were tested for 15 subjects. The age distribution was 25-33 years old and the mean age was 30 years old. Sweating for 15 minutes using a steam generator, then a sufficient amount of Sample Example 1 and Comparative Example 1 (compositions in Table 3) are applied to the hands and centered around the nose and cheeks on the left and right sides, respectively. Rubbed strongly. Sting grade is classified into Intensive stinging, which occurs within 30 seconds according to the time of stimulus response after sample application, Mild stinging for 2.5 minutes, Moderate stinging for 5 minutes, and Delayed stinging for 8 minutes. After the evaluation, the results are shown in Table 6.
상기 표 6의 스팅 테스트 결과에서 확인할 수 있듯이, 소루쟁이 추출물을 포함하는 시험물질은 화장품에서 자극원으로 작용하는 락트산에 의한 피부자극을 크게 감소시킴을 알 수 있다.As can be seen from the test results of Table 6, it can be seen that the test substance containing Soru-Ji extract greatly reduces skin irritation caused by lactic acid acting as a stimulating agent in cosmetics.
실험예 5 : 사용성 평가Experimental Example 5 Usability Evaluation
20-30대 여성 30명의 피검자를 대상으로 소루쟁이 추출물을 포함하는 본 발명의 화장료 조성물의 사용성을 평가하였다. 제조예 1에서 준비한 소루쟁이 추출물이 3.0% 함유된 하기 제형예 4의 조성을 갖는 크림을 피검자에게 10일 동안 도포하였다. 이어, 2% 농도의 락트산을 5일 동안 도포하였고, 이 때 소루쟁이 추출물이 함유된 크림을 같이 사용하도록 하였다. 그런 다음 1주일 경과한 후에 피검자로부터 홍반 발생 유무를 확인하였으며, 그 결과는 표 7에 나타나 있다.Thirty female subjects in their twenties and thirties were evaluated for the usability of the cosmetic composition of the present invention comprising the extract. A cream having the composition of Formulation Example 4, containing 3.0% of the Soruja extract prepared in Preparation Example 1, was applied to the subject for 10 days. Subsequently, lactic acid at a concentration of 2% was applied for 5 days, at which time the cream containing Soru-Jin extract was used together. Then, after one week, the presence of erythema was confirmed by the subject, and the results are shown in Table 7.
상기 표 7의 결과를 통해, 소루쟁이 추출물을 포함하는 본 발명의 화장료 조성물은 화장품의 자극원으로 작용하는 락트산에 의한 피부자극을 완화하여 부작용 (예: 홍반 발생)을 크게 감소시킴을 알 수 있었다.Through the results of Table 7, it can be seen that the cosmetic composition of the present invention containing the extract of Soru-Ji significantly reduces side effects (eg, erythema) by alleviating skin irritation caused by lactic acid acting as a stimulating agent of cosmetics. .
아래와 같은 제형예에서 제조예 1에서 제조한 소루쟁이 추출물을 함유하는 본 발명의 화장료 조성물의 구성을 구체적으로 설명하지만 본 발명의 조성물이 하기 예에만 한정되는 것은 아니다.In the following formulation example, the composition of the cosmetic composition of the present invention containing the soruja extract prepared in Preparation Example 1 will be described in detail, but the composition of the present invention is not limited only to the following examples.
제형예 1: 유연화장수추 Formulation Example 1: Softening Longevity
하기의 표 8과 같이 소루쟁이 추출물을 함유하는 유연화장수를 통상의 방법에 따라 제조하였다.A flexible longevity containing Soru-Ji extract as shown in Table 8 below was prepared according to a conventional method.
제형예 2: 수렴화장수Formulation Example 2: Converging Cosmetic Water
하기의 표 9와 같이 소루쟁이 추출물을 함유하는 수렴화장수를 통상의 방법에 따라 제조하였다.As shown in Table 9 below, astringent cosmetic water containing the extract of Soru-Ji was prepared according to a conventional method.
제형예 3: 영양화장수Formulation Example 3: Nutrients
하기의 표 10과 같이 소루쟁이 추출물을 함유하는 영양화장수를 통상의 방법에 따라 제조하였다.As shown in Table 10 below, the nutritious longevity containing Soru-Ji extract was prepared according to a conventional method.
제형예 4: 영양크림Formulation Example 4: Nutrition Cream
하기의 표 11과 같이 소루쟁이 추출물을 함유하는 영양크림을 통상의 방법에 따라 제조하였다.As shown in Table 11, a nutritive cream containing Soru-Ji extract was prepared according to a conventional method.
제형예 5: 맛사지 크림Formulation Example 5: Massage Cream
하기의 표 12와 같이 소루쟁이 추출물을 함유하는 맛사지 크림을 통상의 방법에 따라 제조하였다.A massage cream containing an extract of Soru-ja extract as shown in Table 12 below was prepared according to a conventional method.
제형예 6: 에센스Formulation Example 6: Essence
하기의 표 13과 같이 소루쟁이 추출물을 함유하는 에센스를 통상의 방법에 따라 제조하였다.As shown in Table 13 below, the essence containing Soru-Ji extract was prepared according to a conventional method.
제형예 7: 팩Formulation Example 7: Pack
하기의 표 14와 같이 소루쟁이 추출물을 함유하는 팩을 통상의 방법에 따라 제조하였다.As shown in Table 14 below, the pack containing the extract was prepared according to a conventional method.
상기에서 살펴본 바와 같이, 본 발명은 소루쟁이 추출물을 유효성분으로 함유하는 피부자극 완화용 화장료 조성물을 제공한다. 본 발명의 소루쟁이 추출물은 일반 화장료에 포함되어 있는 피부자극성 원료에 의해 초래되는 피부자극을 억제할 뿐만 아니라, 피부자극에 의해 유발되는 병적 증상 (예: 피부 염증)을 예방 또는 치료하는데 유용하다.As described above, the present invention provides a cosmetic composition for alleviating the skin irritation, which contains the extract of Sorugung as an active ingredient. The extract of the present invention is useful not only to suppress skin irritation caused by skin irritant raw materials contained in general cosmetics, but also to prevent or treat pathological symptoms (eg, skin inflammation) caused by skin irritation.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.Having described the specific part of the present invention in detail, it is apparent to those skilled in the art that the specific technology is merely a preferred embodiment, and the scope of the present invention is not limited thereto. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050034452A KR100638053B1 (en) | 2005-04-26 | 2005-04-26 | Cosmetic composition for abirritating skin containing extract of rumex crispus as active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050034452A KR100638053B1 (en) | 2005-04-26 | 2005-04-26 | Cosmetic composition for abirritating skin containing extract of rumex crispus as active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100638053B1 true KR100638053B1 (en) | 2006-10-24 |
Family
ID=37621816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050034452A KR100638053B1 (en) | 2005-04-26 | 2005-04-26 | Cosmetic composition for abirritating skin containing extract of rumex crispus as active ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100638053B1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100858628B1 (en) * | 2006-12-29 | 2008-09-17 | 주식회사 코리아나화장품 | Cosmetic Composition for alleviating Skin Irritation Comprising Rumex Crispus L. Extract Stabilized in Nanoliposome |
EP2161025A1 (en) | 2008-09-05 | 2010-03-10 | Engelhard Arzneimittel GmbH & Co. KG | Method for producing an extract from vegetable material of the type Rumex acetosa L. |
KR101128435B1 (en) | 2010-02-03 | 2012-03-23 | 황태혁 | The atto blood skin composition which uses Vitex rotundifolia, cocklebur, Curled Dockand and the soap which uses this |
KR20190041068A (en) | 2017-10-12 | 2019-04-22 | 김민재 | Production method of shampoo using rumex crispus for prevention of hair loss, promotion of hair growth and treatment of seborrheic dermatitis |
KR20200139368A (en) | 2019-06-04 | 2020-12-14 | 김준엽 | Solid fermentation composition manufactured by rumex coreanus and vegetable worms and functional cosmetic composition comprising the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59148723A (en) | 1983-02-15 | 1984-08-25 | Kaichirou Yokogawa | Preparation of liquid for preserving skin health |
JPS63310836A (en) | 1987-06-12 | 1988-12-19 | Satoshi Sasaki | Antitrichophytic remedy |
-
2005
- 2005-04-26 KR KR1020050034452A patent/KR100638053B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59148723A (en) | 1983-02-15 | 1984-08-25 | Kaichirou Yokogawa | Preparation of liquid for preserving skin health |
JPS63310836A (en) | 1987-06-12 | 1988-12-19 | Satoshi Sasaki | Antitrichophytic remedy |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100858628B1 (en) * | 2006-12-29 | 2008-09-17 | 주식회사 코리아나화장품 | Cosmetic Composition for alleviating Skin Irritation Comprising Rumex Crispus L. Extract Stabilized in Nanoliposome |
EP2161025A1 (en) | 2008-09-05 | 2010-03-10 | Engelhard Arzneimittel GmbH & Co. KG | Method for producing an extract from vegetable material of the type Rumex acetosa L. |
KR101128435B1 (en) | 2010-02-03 | 2012-03-23 | 황태혁 | The atto blood skin composition which uses Vitex rotundifolia, cocklebur, Curled Dockand and the soap which uses this |
KR20190041068A (en) | 2017-10-12 | 2019-04-22 | 김민재 | Production method of shampoo using rumex crispus for prevention of hair loss, promotion of hair growth and treatment of seborrheic dermatitis |
KR20200139368A (en) | 2019-06-04 | 2020-12-14 | 김준엽 | Solid fermentation composition manufactured by rumex coreanus and vegetable worms and functional cosmetic composition comprising the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101425031B1 (en) | Cosmetic composition for anti-irritation and skin moisturization containing Citrus junos Siebold seed oil and Mangifera Indica seed oil | |
KR20130023326A (en) | Cosmetic composition containing the sargassum fulvellum, gelidium cartilagineum and hixikia fusiforme okamura extracts | |
KR101387308B1 (en) | Skin whitening composition by using of dendropanax morbifera ferment extract | |
KR102142311B1 (en) | Skin external composition comprising tangeretin | |
KR101055963B1 (en) | Cosmetic composition for promoting exfoliation | |
KR100638053B1 (en) | Cosmetic composition for abirritating skin containing extract of rumex crispus as active ingredient | |
KR20090025497A (en) | The cosmetics composition being contained pau d'arco, tabebuia avellanedae extracts and having the effects of antiphlogistic and abirritation of skin | |
KR102063686B1 (en) | Skin external composition containing extract of soybean root | |
KR102006712B1 (en) | Cosmetic Compositions Containing Extract of Deer Antler | |
CN110072516B (en) | Cosmetic composition comprising extracts of Chinese medicinal materials as effective ingredients | |
KR20080059818A (en) | Cosmetic composition for promoting desquamation containing the extract of cucurbita moschata and castanea crenata as active ingredient | |
KR101934976B1 (en) | Composition for enhancing skin barrier comprising mixture of Diospyros lotus leaf extract and Curcuma longa extract as effective component | |
KR100816265B1 (en) | Cosmetic Composition for Abirritating Skin Containing Extract of Rheum undulatum as Active Ingredient | |
KR101286140B1 (en) | Cosmetic composition for moisturizing and anti-irritation of skin containing polysaccharide from nelumbo nucifera rhizome | |
KR100946584B1 (en) | Cosmetic Composition Comprising Poncirus trifoliata fruit extract and Nymphaea caerulea extract | |
KR101524534B1 (en) | Cosmetic Compositions for Anti-Irritants | |
KR100747502B1 (en) | An anti-irritation complex for skin, and a cosmetic composition containing the same | |
KR20120004021A (en) | Cosmetic composition comprising extracts of cultured wild ginseng root encapsulated in liposome and preparation method thereof | |
KR20100057158A (en) | Cosmetic composition for desquamation containing a papain and the extract of nopal | |
KR20200073523A (en) | Cosmetic Composition for Improving Skin Wrinkle Contaning the Extract of Lithospermum Erythrorhizon | |
KR20160068303A (en) | Cosmetic composition for improving skin dryness, trouble or edema by hangover | |
KR100635782B1 (en) | Cosmetic Composition for Abirritating Skin Containing the Extract of Decorticated Glycine max Merr as Active Ingredient | |
KR102556457B1 (en) | A whitening composition derived from natural products containing a large amount of lipoic acid | |
KR101664878B1 (en) | Cosmetic composition containing fractions of allium hookeri as active ingredient | |
KR100628649B1 (en) | Development of Mung Bean Extract Having Effect on Alleviating Skin Irritation and Cosmetic Composition using thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120928 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20131014 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140925 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160927 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180918 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20191007 Year of fee payment: 14 |